Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma
Wheeler SB, Spees LP, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Dinan MA. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. JCO Oncology Practice 2021, 17: e1895-e1904. PMID: 34138665, PMCID: PMC8678030, DOI: 10.1200/op.20.01082.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaIndex dateCell carcinomaRisk ratioPatterns of usePatients age 80Patients age 18Population-based studyAdjusted risk differenceOral therapyPatient characteristicsContinuous enrollmentHigh frailtyAge 80Agent useRisk differencePatientsDiverse patientsComorbiditiesAge 18Regulatory approvalCarcinomaLog-Poisson modelPatterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.
Wheeler S, Spees L, Jackson B, Baggett C, Wilson L, Greiner M, George D, Scales C, Pritchard J, Dinan M. Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients. Journal Of Clinical Oncology 2021, 39: 279-279. DOI: 10.1200/jco.2021.39.6_suppl.279.Peer-Reviewed Original ResearchMetastatic renal cell carcinoma patientsRenal cell carcinoma patientsCell carcinoma patientsOral anti-cancer agentsCarcinoma patientsRisk ratioPatterns of useRisk differenceGreater comorbidity burdenMetastatic RCC patientsPopulation-based studyPatient-level characteristicsMonths of preAdjusted risk differencePoor quality careComorbidity burdenIndex dateAnti-cancer agentsMetastatic RCCPatient characteristicsContinuous enrollmentRCC patientsTreatment advancesType of insurancePatients